Projects per year
Abstract
AMPK is a sensor of cellular energy status and a promising target for drugs aimed at metabolic disorders. We have studied the selectivity and mechanism of a recently described activator, C2, and its cell-permeable prodrug, C13. C2 was a potent allosteric activator of a1-complexes that, like AMP, also protected against Thr172 dephosphorylation. Compared with AMP, C2 caused only partial allosteric activation of a2-complexes and failed to protect them against dephosphorylation. We show that both effects could be fully restored by exchanging part of the linker between the autoinhibitory and C-terminal domains in a2, containing the equivalent region from a1 thought to interact with AMP bound in site 3 of the ? subunit. Consistent with our results in cell-free assays, C13 potently inhibited lipid synthesis in hepatocytes from wild-type and was largely ineffective in AMPK-knockout hepatocytes; its effects were more severely affected by knockout of a1 than of a2, ß1, or ß2.
Original language | English |
---|---|
Pages (from-to) | 866-879 |
Number of pages | 14 |
Journal | Chemistry & Biology |
Volume | 21 |
Issue number | 7 |
Early online date | 17 Jul 2014 |
DOIs | |
Publication status | Published - 17 Jul 2014 |
Fingerprint
Dive into the research topics of 'Mechanism of Action of Compound-13: an α1-Selective Small Molecule Activator of AMPK'. Together they form a unique fingerprint.Projects
- 1 Finished
-
Non-canonical Pathways for Regulation of AMPK (Senior Investigator Award)
Hardie, G. (Investigator)
1/04/12 → 30/09/17
Project: Research